Brooks Ensign Email & Phone Number
Chief Financial Officer @ Swarmer
5 free lookup(s).
If you need more lookups,
subscriptions start at $34 USD/month.
Brooks Ensign Location
- Los Angeles, CA, US
Brooks Ensign Work
- 2026 -now Chief Financial Officer @
- 2010 -2026 Finance, Accounting and Data Analytics Instructor @ National University
- 2025 -2026 Acting CFO and Controller @ Mira Pharmaceuticals and Telomir Phramaceuticals (NASDAQ: MIRA and TELO)
- 2025 -2025 Interim Chief Financial Officer @
- 2025 -2026 (Interim) Acting CFO and Controller @ Mira Pharmaceuticals and Telomir Phramaceuticals (NASDAQ: MIRA and TELO)
- 2022 -2024 VP, Controller (Nasdaq: APTO) @
- 2022 -2025 Corporate Finance Instructor @
- 2021 -2022 Acting CFO and VP, Global Corporate Controller (Nasdaq: SVCO) @
- 2021 -2021 VP of Financial Reporting @
- 2017 -2020 Interim Controller roles and Consulting @ Interim Roles
- 2016 -2017 Controller @ Nervana Systems (acquired by Intel)
- 2015 -2015 Controller @
- 2013 -2015 Controller @
- 2010 -2026 Finance, Accounting and Data Analytics Instructor @ National University
- 2021 -2022 VP, Global Corporate Controller and Acting CFO (Nasdaq: SVCO) @
- 2010 -2012 Controller (Interim) @
- 2010 -2011 Financial Planning and Analysis (consultant) @
- 2008 -2009 Director of Financial Planning and Analysis @
- 1995 -2008 Director of Corporate Development @ Bausch Health (formerly Valeant Pharmaceuticals, formerly ICN Pharmaceuticals)
- 1988 -1993 Ensign Ensign (US Navy Officer, Combat Veteran) @
Brooks Ensign Education
- Udemy Alumni
(Artificial Intelligence and Business)
2016-2025 - UC San Diego
Accounting Certificate ( All CPA coursework completed) and AIPB Bookkeeper certification (Accounting)
2005-2008 - Harvard Business School and Harvard College
MBA (Navy ROTC, Phoenix-S.K.)
- National University
Master's degree (Accounting)
- SEC Institute
SEC Reporting Coursework
Brooks Ensign Skills
- Medical Diagnostics
- Financial Advisory
- SEC
- Variance Analysis
- Consulting
- Clinical Trials
- Stock Exchange
- Channel
- International Business Development
- Screening
- Insurance
- Sales
- Accruals
- Cost
- Learning C++
- Interpretations
- Clinical Research
- Biotechnology
- Operating Expenses
- Market Research
- Alzheimer's disease
- Regulatory Affairs
- Biostatistics
- Finance
- Investor Relations
- SEC filings
- Covenant Compliance
- Proxy
- SAN
- Hospital Sales
- Adoption
- Prenatal Care
- SEP IRA
- Cross Functional Team Leadership
- Clinical Development
- Scholarships
- Product Forecasting
- Assessment
- Perspectives
- Texas
- Article
- Management
- Tsx
- Design
- Insurance Planning
- Revenue
- Financial Statements
- Public Relations
- Patents
- Statistics
- Real Estate Development
- Senate
- Hiring
- Beijing
- Initiation
- Leadership
- Auditing
- Publications
- Accounting
- Quarter
- Year End Close
- Human Resources
- Primary Research
- Mergers
- Parkinson's
- Restatements
- Securities Regulation
- Gene Therapy
- Functional Genomics
- Neurodegeneration
- Valuation
- Year End
- Dermatology
- Guidance
- Portfolio Management
- Lobbying
- Forecasting
- Foundation
- Strategic Initiatives
- Automotive
- Healthcare
- Offering
- Asia
- Nyse
- Internet of Things
- From Scratch
- Strategy
- Organizational Restructuring
- Product Rationalization
- Branding
- Cash Flow Forecasting
- Ista
- Budgeting
- Acquisitions
- Medicine
- Microsoft Excel
- Financial Goals
- Testing
- Drug Development
- Policy
- Bookkeeping
- Monthly Close
- Capitol Hill
- Diabetes
- Congressional Lobbying
- Operational Excellence
- Part Time
- Product Launch
- Shareholder
- American
- Research
- Eastern Europe
- Reporting
- Close Process
- Venture Capital
- Internet Security
- XBRL
- Commercial Real Estate
- Controller
- Board of Directors
- Analysis
- Partnerships
- R&D
- Marketing Research
- Strategic Finance
- R
- CPA
- S 1
- Espp
- Ion
- Cash Flow
- Corporate Finance
- Coordination
- Retail
- Spectrum
- Controllers
- Tissue
- Applications
- Financial Modeling
- Business Expansion
- Debate
- Intel
- Universities
- Business Development
- Negotiation
- ERP
- Business Operations
- Strategic Planning
- Active
- Scientific
- Licensing
- Clinical Data
- Drug Discovery
- Degrees
- Marketing
- Toronto
- Adaptive
- Project Planning
- GAAP
- Switzerland
- Project
- Sarbanes Oxley Act
- House
- Health Sciences
- Investment Banking
- Nasdaq
- Tear
- Intellectual Property
- Classroom
- Corporate Development
- Advocacy
- Pharmaceutical Consulting
- Pivotal
- Clinical Documentation
- Covering
- Poland
- Responsibility
- Intellectual Asset Management
- Usa
- Therapists
- Policies and Procedures
- Phoenix
- International
- Acquisition Negotiations
- Conceived
- Tax Planning
- Portfolio
- Accounting Policy
- Navy
- Start Ups
- Teaching
- Stock Option
- Tax
- Data Analytics
- Diagnostics
- Process Improvement
- Subsidiaries
- Dallas
- Medical Devices
- Global Marketing
- Corporate Headquarters
- San Diego
- Financial Services
- SAS
- Equities
- Compliance
- Windows NT
- Business Planning
- Pharmaceutics
- Financial Integration
- Manufacturing
- Internal Controls
- Financial Analysis
- Biologics
- Military
- Investor Relations Support
- Budgets
- Financial Transactions
- Business Strategy
- Central Nervous System
- Financial Reporting
- Halo
- IFRS
- Due Diligence
- Corporate Financial Reporting
- Pharmaceutical Industry
- Cost Benefit
- Cost Management
- Mergers and Acquisitions
- Consolidated Reporting
- Epilepsy
- FDA
- Commercialization
Brooks Ensign Summary
- Brooks Ensign, based in Los Angeles, CA, US, is currently a Chief Financial Officer at Swarmer. Brooks Ensign brings experience from previous roles at National University, Mira Pharmaceuticals and Telomir Phramaceuticals (NASDAQ: MIRA and TELO) and NuvOx Therapeutics. Brooks Ensign holds a 2016 - 2025 Udemy Alumni. With a robust skill set that includes Medical Diagnostics, Financial Advisory, SEC, Variance Analysis, Consulting and more. Brooks Ensign has 1 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Brooks Ensign?
Find contact details for 700 million professionals.
G2 Crowd Trusted
300K+ Plugin Users
© 2026 RocketReach.co